(WSJ) – Artificial intelligence could lead to new cures and better diagnostics, but let’s hope bureaucrats don’t get in the way. An early test comes Wednesday when an outside advisory committee to the Food and Drug Administration will review Grail’s multi-cancer early detection test.

Grail’s Galleri test leads a fast-developing field of liquid biopsies that screen asymptomatic patients for signals of cancer in blood. The goal is to diagnose cancers earlier when they are easier to treat, and the odds of survival are higher. (Read More)